Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.

By Claus ThestrupCEO, Sweden
Flerie

Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.

CEO Jenny Sundqvist gave a very confident impression of why the Conclude phase lll study with Cobitolimod were delayed, how they will speed up the process and what potential triggers to look for in Q4-2023. Further the CEO confirmed earlier estimates for growth in the total addressable UC market.

CDO Dr. Eva Arlander deep dived into the recently announced outcome of the PK-study with Cobitolimod 500 mg dose and how they will use positive data going forward.

Listen to the interview: https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod

Disclaimer:

HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 09:35 AM 03-29-2023.

Flerie

41SEK28.03.2023, 18.00

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Read more on company page

Forum discussions

DISCLAIMER: HC ANDERSEN CAPITAL RECEIVES PAYMENT FROM INDEX PHARMACEUTICALS FOR A CORPORATE VISIBILITY/DIGITAL IR SUBSCRIPTION AGREEMENT. Dansk...
10/17/2022, 8:11 AM
by Olivier A. de Goeij
0
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team